secwatch.observer — SEC 8-K summary
======================================

Issuer:     INFINITY PHARMACEUTICALS, INC. (—)
CIK:        0001113148
Form:       8-K
Filed at:   2023-04-07T23:59:59+00:00
Accession:  0001140361-23-017328
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Infinity Pharma receives second Nasdaq deficiency; market value below $50M
--------------------------------------------------------------------------

- Received April 4, 2023 letter: market value of listed securities below $50M for 30 consecutive days (Minimum MVLS Requirement).
- Also non-compliant with total assets/revenue rule requiring at least $50M each for most recent fiscal year.
- Has 180 days, until October 2, 2023, to regain compliance via $50M+ market value close for 10 consecutive days.
- Already out of compliance with minimum $1.00 bid price rule since December 2022 (previously disclosed).
- Failure to comply by Oct 2 could lead to delisting; may appeal or apply to transfer to Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1113148/000114036123017328/0001140361-23-017328-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1113148/000114036123017328/brhc10051174_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-017328

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer